How therapeutic drug monitoring can help to personalise dosing of anti-tnf monoclonal antibodies in patients with chronic inflammatory diseases
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: VANDE CASTEELE, Niels (KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium)
Therapeutic drug monitoring (TDM) of anti-tumour necrosis factor (anti-TNF) monoclonal antibodies with measurements of drug serum levels and anti-drug antibodies (ADA) holds the potential to further unravel how pharmacokinetics (PK) and immunogenicity influence disease activity and clinical (non-)response in rheumatoid arthritis and inflammatory.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.